Recent advances in genome editing tools using endonucleases such as TALENs, ZFNs, and CRISPRs, combined with genomic engineering technologies, have opened up a wide range of opportunities from applications in the basic sciences and disease biology research, to the potential for clinical applications and the development of new diagnostic tools. This complete guide to endonuclease-based genomic engineering gives readers a thorough understanding of this rapidly expanding field. Chapters cover the discovery, basic science, and application of these techniques, focusing particularly on their potential relevance to the treatment of cancer, and cardiovascular and immunological disease. The final section discusses the legal and ethical issues which accompany the technology. Providing authoritative coverage of the potential that genome editing and engineering have, this is an ideal reference for researchers and graduate students and those working in the biotechnology and pharmaceutical industries, as well as in a clinical setting.
George M. Church - Harvard University, Massachusetts and Massachusetts Institute of Technology
Norbert Perrimon - Harvard Medical School, Boston
Rodger Novak - President, Director and Chair of the Board CRISPR Therapeutics AG, Switzerland
Francisco Juan Martinez Mojica - Universidad de Alicante, Spain
Shamim Herbert Rahman - Senior Research Scientist, Novo Nordisk A/S, Måløv, Denmark
Keiji Nishida - Kobe University, Japan
Antonio Russo - 'P. Giaccone' University Hospital, University of Palermo, Italy
* Views captured on Cambridge Core between #date#. This data will be updated every 24 hours.
Usage data cannot currently be displayed.